OBJECTIVE: Frontotemporal lobar degeneration (FTLD) is characterized by impairments in social, behavioral, and/or language function, but postmortem studies indicate that multiple neuropathological entities lead to FTLD. This study assessed whether specific clinical features predict the underlying pathology. METHODS: A clinicopathological correlation was performed on 90 consecutive patients with a pathological diagnosis of frontotemporal dementia and was compared with an additional 24 cases accrued during the same time period with a clinical diagnosis of FTLD, but with pathology not typically associated with frontotemporal dementia. RESULTS: Postmortem examination showed multiple pathologies including tauopathies (46%), FTLD with ubiquitin-positive inclusions (29%), and Alzheimer's disease (17%). The pathological groups manifested some distinct demographic, clinical, and neuropsychological features, although these attributes showed only a statistical association with the underlying pathology. FTLD with ubiquitin-positive inclusions was more likely to present with both social and language dysfunction, and motor neuron disease was more likely to emerge in these patients. Tauopathies were more commonly associated with an extrapyramidal disorder. Alzheimer's disease was associated with relatively greater deficits in memory and executive function. INTERPRETATION: Clinical and neuropsychological features contribute to delineating the spectrum of pathology underlying a patient diagnosed with FTLD, but biomarkers are needed that, together with the clinical phenotype, can predict the underlying neuropathology. Ann Neurol 2006;59:952-962
OBJECTIVE: Frontotemporal lobar degeneration (FTLD) is characterized by impairments in social, behavioral, and/or language function, but postmortem studies indicate that multiple neuropathological entities lead to FTLD. This study assessed whether specific clinical features predict the underlying pathology. METHODS: A clinicopathological correlation was performed on 90 consecutive patients with a pathological diagnosis of frontotemporal dementia and was compared with an additional 24 cases accrued during the same time period with a clinical diagnosis of FTLD, but with pathology not typically associated with frontotemporal dementia. RESULTS: Postmortem examination showed multiple pathologies including tauopathies (46%), FTLD with ubiquitin-positive inclusions (29%), and Alzheimer's disease (17%). The pathological groups manifested some distinct demographic, clinical, and neuropsychological features, although these attributes showed only a statistical association with the underlying pathology. FTLD with ubiquitin-positive inclusions was more likely to present with both social and language dysfunction, and motor neuron disease was more likely to emerge in these patients. Tauopathies were more commonly associated with an extrapyramidal disorder. Alzheimer's disease was associated with relatively greater deficits in memory and executive function. INTERPRETATION: Clinical and neuropsychological features contribute to delineating the spectrum of pathology underlying a patient diagnosed with FTLD, but biomarkers are needed that, together with the clinical phenotype, can predict the underlying neuropathology. Ann Neurol 2006;59:952-962
Authors: G Wightman; V E Anderson; J Martin; M Swash; B H Anderton; D Neary; D Mann; P Luthert; P N Leigh Journal: Neurosci Lett Date: 1992-05-25 Impact factor: 3.046
Authors: E D Roberson; J H Hesse; K D Rose; H Slama; J K Johnson; K Yaffe; M S Forman; C A Miller; J Q Trojanowski; J H Kramer; B L Miller Journal: Neurology Date: 2005-09-13 Impact factor: 9.910
Authors: Julene K Johnson; Janine Diehl; Mario F Mendez; John Neuhaus; Jill S Shapira; Mark Forman; Dennis J Chute; Erik D Roberson; Catherine Pace-Savitsky; Manuela Neumann; Tiffany W Chow; Howard J Rosen; Hans Forstl; Alexander Kurz; Bruce L Miller Journal: Arch Neurol Date: 2005-06
Authors: John Joseph Downes; Nicholas M. Priestley; Mark Doran; Jose Ferran; Eric Ghadiali; Paul Cooper Journal: Behav Neurol Date: 1998 Impact factor: 3.342
Authors: David S Knopman; Bradley F Boeve; Joseph E Parisi; Dennis W Dickson; Glenn E Smith; Robert J Ivnik; Keith A Josephs; Ronald C Petersen Journal: Ann Neurol Date: 2005-04 Impact factor: 10.422
Authors: M Stevens; C M van Duijn; W Kamphorst; P de Knijff; P Heutink; W A van Gool; P Scheltens; R Ravid; B A Oostra; M F Niermeijer; J C van Swieten Journal: Neurology Date: 1998-06 Impact factor: 9.910
Authors: Prashanthi Vemuri; Gyorgy Simon; Kejal Kantarci; Jennifer L Whitwell; Matthew L Senjem; Scott A Przybelski; Jeffrey L Gunter; Keith A Josephs; David S Knopman; Bradley F Boeve; Tanis J Ferman; Dennis W Dickson; Joseph E Parisi; Ronald C Petersen; Clifford R Jack Journal: Neuroimage Date: 2010-12-31 Impact factor: 6.556
Authors: David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski Journal: Ann Neurol Date: 2012-10-04 Impact factor: 10.422
Authors: Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2007-06-20 Impact factor: 17.088
Authors: Han Soo Yoo; Seok Jong Chung; Soo-Jong Kim; Jung Su Oh; Jae Seung Kim; Byoung Seok Ye; Young Ho Sohn; Phil Hyu Lee Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-04 Impact factor: 9.236
Authors: Alberto Lleó; David J Irwin; Ignacio Illán-Gala; Corey T McMillan; David A Wolk; Edward B Lee; Vivianna M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman Journal: JAMA Neurol Date: 2018-06-01 Impact factor: 18.302